Lantheus (NASDAQ:LNTH) Trading Down 4.3% - Time to Sell?

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) shares were down 4.3% during mid-day trading on Tuesday . The company traded as low as $110.24 and last traded at $110.54. Approximately 296,201 shares traded hands during trading, a decline of 69% from the average daily volume of 953,683 shares. The stock had previously closed at $115.45.

Wall Street Analyst Weigh In

LNTH has been the topic of several recent research reports. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target on the stock. B. Riley increased their price target on Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. JMP Securities cut their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research report on Thursday, August 1st. Truist Financial dropped their target price on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. Finally, Leerink Partners upped their target price on Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $126.00.

Lantheus Trading Down 0.4 %

The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The stock has a market capitalization of $7.98 billion, a price-to-earnings ratio of 18.93 and a beta of 0.51. The business has a fifty day simple moving average of $108.30 and a 200 day simple moving average of $95.24.

Insider Buying and Selling

In related news, President Paul Blanchfield sold 2,000 shares of the firm's stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now owns 98,980 shares of the company's stock, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, President Paul Blanchfield sold 2,000 shares of the company's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the transaction, the president now directly owns 98,980 shares in the company, valued at approximately $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Lantheus

A number of hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 208 shares during the period. Fidelis Capital Partners LLC purchased a new stake in shares of Lantheus in the first quarter worth about $34,000. Signaturefd LLC boosted its holdings in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 92 shares during the period. Nkcfo LLC purchased a new position in Lantheus during the second quarter worth about $47,000. Finally, UMB Bank n.a. increased its position in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 126 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.